Angiopoietins in tumours: The angiogenic switch

Journal of Pathology

Volumn 204, Issue 1, 2004, Pages 1-10

  Tait, Catherine R ^a   Jones, Pamela F ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Angiogenesis; Angiogenic switch; Angiopoietins; Tumour

Indexed keywords

ANGIOPOIETIN; ANGIOPOIETIN 1; ANGIOPOIETIN 2; CD11B ANTIGEN; CD18 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GLYCOPROTEIN P 15095; GROWTH FACTOR RECEPTOR; INTERLEUKIN 10; MESSENGER RNA; PROTEIN TYROSINE KINASE; VASCULOTROPIN;

ANGIOGENESIS; ASTROCYTOMA; BILIARY TRACT TUMOR; BRAIN TUMOR; BREAST CANCER; CARCINOGENESIS; COLORECTAL CANCER; DRUG TARGETING; FEMALE GENITAL SYSTEM; FEMALE GENITAL TRACT CANCER; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE TARGETING; GLIOBLASTOMA; GLIOMA; HEMATOLOGIC MALIGNANCY; HUMAN; KAPOSI SARCOMA; KIDNEY CARCINOMA; LIVER TUMOR; LUNG CANCER; MELANOMA; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN LOCALIZATION; PUBLICATION; QUANTITATIVE ANALYSIS; REVIEW; SKIN TUMOR; SPROUTING; SQUAMOUS CELL CARCINOMA; STOMACH CANCER; THYROID CANCER; TUMOR VASCULARIZATION;

ANGIOPOIETIN-2; ANGIOPOIETINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; UP-REGULATION;

EID: 4544290590     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/path.1618     Document Type: Review

References (96)

1. Folkman J. How is blood vessel growth regulated in normal and neoplastic tissue? Cancer Res 1986; 46: 467-473.
2. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990; 82: 4-6.
3. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nature Med 2003; 9: 669-676.
4. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002; 29: 15-18.
5. Jones PF. Not just angiogenesis - wider roles for the angiopoietins. J Pathol 2003; 201: 515-527.
6. Davis S, Aldrich TH, Jones PF, et al. Isolation of angiopoietin-1, a ligand for the Tie2 receptor, by secretion trap expression cloning. Cell 1996; 87: 1161-1169.
7. Maisonpierre PC, Suri C, Jones PF, et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in-vivo angiogenesis. Science 1997; 277: 55-60.
8. Kim I, Kim JH, Moon SO, Kwak HJ, Kim NG, Koh GY. Angiopoietin-2 at high concentration can enhance endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Oncogene 2000; 19: 4549-4552.
9. Suri C, Jones PF, Patan S, et al. Requisite role of angiopoietin-1, a ligand for the Tie2 receptor, during embryonic angiogenesis. Cell 1996; 87: 1171-1180.
10. Gravallese EM, Pettit AR, Lee R, et al. Angiopoietin-1 is expressed in the synovium of patients with rheumatoid arthritis and is induced by tumour necrosis factor alpha. Ann Rheum Dis 2003; 62: 100-107.
11. Kim I, Kim JH, Ryu YS, Liu M, Koh GY. Tumour necrosis factor-α upregulates angiopoietin-2 in human umbilical vein endothelial cells. Biochem Biophys Res Commun 2000; 269: 361-365.
12. Ray PS, Estrada-Hernandez T, Sasaki H, Zhu L, Maulik N. Early effects of hypoxia/reoxygenation on VEGF, ang-1, ang-2 and their receptors in the rat myocardium: implications for myocardial angiogenesis. Mol Cell Biochem 2000; 213: 145-153.
13. Oh H, Tagaki H, Suzama K, Otani A, Matsumura M, Honda Y. Hypoxia and vascular endothelial growth factor up-regulate angiopoietin-2 in bovine microvascular endothelial cells. J Biol Chem 1999; 274: 15732-15739.
14. Krikun G, Schatz F, Finlay T, et al. Expresion of angiopoietin-2 by human endometrial endothelial cells: regulatin by hypoxia and inflammation. Biochem Biophys Res Commun 2000; 275: 159-163.
15. Mandriota SJ, Pyke C, Di Sanza C, Quinodoz P, Pittet B, Pepper MS. Hypoxia-inducible angiopoietin-2 expression is mimicked by iodonium compounds and occurs in the rat brain and skin in response to systemic hypoxia and tissue ischemia. Am J Pathol 2000; 156: 2077-2089.
16. Yuan HT, Yang SP, Woolf AS. Hypoxia up-regulates angiopoietin-2, a Tie-2 ligand, in mouse mesangial cells. Kidney Int 2000; 58: 1912-1919.
17. Mandriota SJ, Pepper MS. Regulation of angiopoietin-2 mRNA levels in bovine microvascular endothelial cells by cytokines and hypoxia. Circ Res 1998; 83: 852-859.
18. Pichiule P, LaManna JC. Angiopoietin-2 and rat brain capillary remodelling during adaptation and deadaptation to prolonged mild hypoxia. J Appl Physiol 2002; 93: 1131-1139.
19. Ghafar MA, Anastasiadis AG, Olsson LE, et al. Hypoxia and angiogenic response in the partially obstructed rat bladder. Lab Invest 2002; 82: 903-909.
20. Park YS, Kim NH, Jo I. Hypoxia and vascular endothelial growth factor acutely up-regulate angiopoietin-1 and Tie2 mRNA in bovine retinal pericytes. Microvasc Res 2003; 65: 125-131.
21. Enholm B, Paavonen A, Ristimaki A, et al. Comparison of VEGF, VEGF-B, VEGF-C and Ang-a mRNA regulation by serum growth factors, oncoproteins and hypoxia. Oncogene 1997; 14: 2475-2483.
22. Currie MJ, Gunningham SP, Turner K, et al. Expression of the angiopoietins and their receptor Tie2 in human renal clear cell carcinomas; regulation by the von Hippel-Lindau gene and hypoxia. J Pathol 2002; 198: 502-510.
23. Ye F, Florian M, Magder SA, Hussain SNA. Regulation of angiopoietin and Tie-2 receptor expression in non-reproductive tissues by estrogen. Steroids 2002; 67: 305-310.
24. Richard C, Kim G, Koikawa Y, et al. Androgens modulate the balance between VEGF and angiopoietin expression in prostate epithelial and smooth muscle cells. Prostate 2002; 50: 83-91.
25. Haralabopoulos GC, Grant DS, Kleinman HK, Maragoudakis ME. Thrombin promotes endothelial cell alignment in matrigel in vitro and angiogenesis in vivo. Am J Physiol 1997; 273: 239-245.
26. Huang Y-Q, Li J-J, Hu L, Lee M, Karpatkin S. Thrombin induces increased expression and secretion of angiopoietin-2 from human umbilical vein endothelial cells. Blood 2002; 99: 1646-1650.
27. Zagzag D, Hooper A, Friedlander DR, et al. In situ expression of angiopoietins in astrocytomas identifies angiopoietin-2 as an early marker of tumour angiogenesis. Exp Neurol 1999; 159: 391-400.
28. Ding H, Roncari L, Wu X, et al. Expression and hypoxic regulation of angiopoietins in human astrocytomas. Neurooncology 2001; 3: 1-10.
29. Stratmann A, Risau W, Plate KH. Cell type-specific expression of angiopoietin-1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis. Am J Pathol 1998; 153: 1459-1465.
30. Audero E, Cascone I, Zanon I, et al. Expression of angiopoietin-1 in human glioblastomas regulates tumour-induced angiogenesis. Arterioscler Thromb Vasc Biol 2001; 21: 536-541.
31. Vajkoczy P, Farhadi M, Gaumann A, et al. Microtumour growth initiates angiogenic sprouting with simultaneous expression of VEGF, VEGFR-2, and angiopoietin-2. J Clin Invest 2002; 109: 777-785.
32. Hu B, Guo P, Fang Q, et al. Angiopoietin-2 induces human glioma invasion through the activation of matrix metalloprotease-2. Proc Natl Acad Sci USA 2003; 100: 8904-8909.
33. Koga K, Todaka T, Morioka M, et al. Expression of angiopoietin-2 in human glioma cells and its role for angiogenesis. Cancer Res 2001; 61: 6248-6254.
34. Osada H, Tokunaga T, Hatanaka H, et al. Gene expression of angiogenesis related factors in glioma. Int J Oncol 2001; 18: 305-309.
35. Peoch M, Farion R, Hiou A, Le Bas JF, Pasquier B, Remy C. Immunohistochemical study of VEGF, angiopoietin 2 and their receptors in the neovascularization following microinjection of C6 glioma cells into rat brain. Anticancer Res 2002; 22: 2147-2151.
36. Holash J, Maisonpierre PC, Compton C, et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999; 284: 1994-1998.
37. Eggert A, Ikegaki N, Kwiatkowski J, Zhao H, Brodeur GM, Himelstein BP. High-level expression of angiogenic factors is associated with advanced tumor stage in human neuroblastomas. Clin Cancer Res 2000; 6: 1900-1908.
38. Hayes AJ, Huang W-G, Yu J, et al. Expression and function of angiopoietin-1 in breast cancer. Br J Cancer 2000; 83: 114-1160.
39. Sfiligoi C, De Luca A, Cascone I, et al. Angiopoietin-2 expression in breast cancer correlates with lymph node invasion and short survival. Int J Cancer 2003; 103: 466-474.
40. Calvo A, Yokoyama Y, Smith LE, et al. Inhibition of the mammary carcinoma angiogenic switch in C3(1)/SV40 transgenic mice by a mutated form of human endostatin. Int J Cancer 2002; 101: 224-234.
41. Stratmann A, Acker T, Burger AM, Amann K, Risau W, Plate KH. Differential expression of tumour angiogenesis by Tie2 and vascular endothelial growth factor receptor-2 dominant-negative receptor mutants. Int J Cancer 2001; 91: 273-282.
42. Carter WB, Ward MD. HER2 regulatory control of angiopoietin-2 in breast cancer. Surgery 2000; 128: 153-158.
43. Monsky WL, Carreira CM, Tsuzuki Y, Gohongi T, Fukumura D, Jain RK. Role of host microenvironment in angiogenesis and microvascular functions in human breast cancer xenografts: mammary fat pad versus cranial tumours. Clin Cancer Res 2002; 8: 1008-1013.
44. Currie MJ, Gunningham SP, Han C, et al. Angiopoietin-1 is inversely related to thymidine phosphorylase expression in human breast cancer, indicating a role in vascular remodelling. Clin Cancer Res 2001; 7: 918-927.
45. Caine GJ, Blann AD, Stonelake PS, Ryan P, Lip GYH. Plasma angiopoietin-1, angiopoietin-2 and Tie2 in breast and prostate cancer: a comparison with VEGF and Flt-1. Eur J Clin Invest 2003; 33: 883-890.
46. Shirakawa K, Shibuya M, Heike Y, et al. Tumour infiltrating endothelial cells and endothelial precursor cells in inflammatory breast cancer. Int J Cancer 2002; 99: 344-351.
47. Yu Y, Varughese J, Brown LF, Mulliken JB, Bischoff J. Increased Tie2 expression, enhanced response to angiopoietin-1, and dysregulated angiopoietin-2 expression in hemangioma-derived endothelial cells. Am J Pathol 2001; 159: 2271-2280.
48. Tanaka S, Mori M, Sakamoto Y, Makuuchi M, Sugimachi K, Wands JR. Biological significance of angiopoietin expression in human hepatocellular carcinoma. J Clin Invest 1999; 103: 341-345.
49. Kuroda H, Ohtsuru A, Futakuchi M, et al. Distinctive gene expression of receptor-type tyrosine kinase families during rat hepatocarcinogenesis. Int J Mol Med 2002; 9: 473-480.
50. Mitsuhashi N, Shimizu H, Ohtsuka M, et al. Angiopoietins and Tie-2 expression in angiogenesis and proliferation of human hepatocellular carcinoma. Hepatology 2003; 37: 1105-1113.
51. Moon WS, Rhyu KH, Kang MJ, et al. Overexpression of VEGF and angiopoietin-2: a key to high vascularity of hepatocellular carcinoma? Mod Pathol 2003; 16: 552-557.
52. Sugimachi K, Tanaka S, Taguchi K, Aishima S, Shimada M, Tsuneyoshi M. Angiopoietin switching regulates angiogenesis and progression of human hepatocellular carcinoma. J Clin Pathol 2003; 56: 854-860.
53. Paradis V, Bieche I, Dargere D, et al. A quantitative gene expression study suggests a role for angiopoietins in focal nodular hyperplasia. Gastroenterology 2003; 124: 651-659.
54. Yoshida Y, Oshika Y, Fukushima Y, et al. Expression of angiostatic factors in colorectal cancer. Int J Oncol 1999; 15: 1221-1225.
55. Ahmed SA, Liu W, Jung YD, et al. Differential expression of angiopoietin-2 in colon carcinoma. Cancer 2001; 92: 1138-1143.
56. Ogawa M, Yamamoto H, Nagano H, et al. Hepatic expression of Ang-2 RNA in metastatic colorectal cancer. Hepatology 2004; 39: 528-539.
57. Takahama M, Tsutsumi M, Tsujiuchi T, et al. Enhanced expression of Tie2 and its ligand angiopoietin-1, vascular endothelial growth factor and CD31 in human non-small cell lung carcinomas. Clin Cancer Res 1999; 5: 2506-2510.
58. Wong MP, Chan SY, Fu KH, et al. The angiopoietins, Tie2 and vascular endothelial growth factor are differentially expressed in the transformation of normal to non-small cell lung carcinomas. Lung Cancer 2000; 29: 11-22.
59. Tanaka F, Ishikawa S, Yanagihara K, et al. Expression of angiopoietins and its clinical significance in non-small cell lung cancer. Cancer Res 2002; 62: 7124-7129.
60. Hatanaka H, Abe Y, Naruke M, et al. Significant correlation between interleukin 10 expression and vascularization through angiopoietin/Tie2 networks in non small cell lung cancer. Clin Cancer Res 2001; 7: 1287-1292.
61. Watarai M, Miwa H, Shikami M, et al. Expression of endothelial cell-associated molecules in AML cells. Leukemia 2002; 16: 112-119.
62. Muller A, Lange K, Gaiser T, et al. Expression of angiopoietin-1 and its receptor TEK in haematopoietic cells from patients with myeloid leukaemia. Leuk Res 2002; 26: 163-168.
63. Giuliani N, Colla S, Lazzaretti M, et al. Proangiogenic properties of human myeloma cells: production of angiopoietin-1 and its potential relationship to myeloma-induced angiogenesis. Blood 2003; 102: 638-645.
64. Etoh T, Inoue H, Tanaka S, Barnard GF, Kitano S, Mori M. Angiopoietin-2 is related to tumour angiogenesis in gastric carcinoma: possible in vivo regulation via induction of proteases. Cancer Res 2001; 61: 2145-2153.
65. Lee JH, Koh JT, Shin BA, et al. Comparative study of angiostatic and anti-invasive gene expressions as prognostic factors in gastric cancer. Int J Oncol 2001; 18: 355-361.
66. Shim WSN, Teh M, Mack POP, Ge R. Inhibition of angiopoietin-1 expression in tumour cells by an anti-sense RNA approach inhibited xenograft tumour growth in immunodeficient mice. Int J Cancer 2001; 94: 6-15.
67. Shim WSN, Teh M, Bapna A, et al. Angiopoietin-1 promotes tumour angiogenesis and tumour vessel plasticity of human cervical cancer in mice. Exp Cell Res 2002; 279: 299-309.
68. Martoglio AM, Tom BD, Starkey M, Corps AN, Charnock-Jones DS, Smith SK. Changes in tumourigenesis and angiogenesis related gene transcript abundance profiles in ovarian cancer detected by tailored high density cDNA arrays. Mol Med 2000; 6: 750-765.
69. Zhang L, Yang N, Park J-W, et al. Tumour-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilises host vasculature, supporting angiogenesis in ovarian cancer. Cancer Res 2003; 63: 3403-3412.
70. Guschmann M, Henrich W, Dudenhausen JW. Chorioangiomas - new insights into a well-known problem. II. An immuno-histochemical investigation of 136 cases. J Perinat Med 2003; 31: 170-175.
71. Pomyje J, Zivny JH, Stopka T, Simak J, Vankova H, Necas E. Angiopoietin-1, angiopoietin-2 and Tie2 in tumour and non-tumour tissues during growth of experimental melanoma. Melanoma Res 2001; 11: 639-643.
72. Hawighorst T, Skobe M, Streit M, et al. Activation of the Tie2 receptor by angiopoietin-1 enhances tumour vessel maturation and impairs squamous cell carcinoma growth. Am J Pathol 2002; 160: 1381-1392.
73. Brown LF, Dezube BJ, Tognazzi K, Dvorak HF, Yancopoulos GD. Expression of Tie1, Tie2 and angiopoietins 1, 2 and 4 in Kaposi's sarcoma and cutaneous angiosarcoma. Am J Pathol 2000; 156: 2179-2183.
74. Mitsutake N, Namba H, Takahara K, et al. Tie2 and angiopoietin-1 expression in human thyroid cancers. Thyroid 2002; 12: 95-99.
75. Bunone G, Vigneri P, Mariani L, et al. Expression of angiogenesis stimulators and inhibitors in human thyroid tumours and correlation with clinical pathological features. Am J Pathol 1999; 155: 1967-1976.
76. Nagata J, Kijima H, Hatanaka H, et al. Angiopoietin-1 and vascular endothelial growth factor expression in human esophageal cancer. Int J Mol Med 2002; 10: 423-426.
77. Wurmbach J-H, Hammerer P, Sevinc S, Huland H, Ergun S. The expression of angiopoietins and their receptor Tie2 in human prostate carcinoma. Anticancer Res 2000; 20: 5217-5220.
78. Favier J, Plouin P-F, Corvol P, Gasc J-M. Angiogenesis and vascular architecture in pheochromocytomas: distinctive traits in malignant tumors. Am J Pathol 2002; 161: 1235-1246.
79. Zagzag D, Amirnovin R, Greco MA, et al. Vascular apoptosis and involution in gliomas precede neovascularization: a novel concept for glioma growth and angiogenesis. Lab Invest 2000; 61: 837-849.
80. Holash J, Wiegand SJ, Yancopoulos GD. New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF. Oncogene 1999; 18: 5356-5362.
81. Ruohola JK, Valve EM, Karkkainen MJ, Joukov V, Alitalo K, Harkonen PL. Vascular endothelial growth factors are differentially regulated by steroid hormones and antiestrogens in breast cancer cells. Mol Cell Endocrinol 1999; 149: 29-40.
82. Bogin L, Degani H. Hormonal regulation of VEGF in orthotopic MCF7 human breast cancer. Cancer Res 2002; 62: 1948-1951.
83. Buteau-Lozano H, Ancelin M, Lardeux B, Milanini J, Perrot-Applanat M. Transcriptional regulation of vascular endothelial growth factor by estradiol and tamoxifen in breast cancer cells: a complex interplay between estrogen receptors alpha and beta. Cancer Res 2002; 62: 4977-4984.
84. Hyder SM, Huang JC, Nawaz Z, et al. Regulation of vascular endothelial growth factor expression by estrogens and progestins. Environ Health Perspect 2000; 108(Suppl 5): 785-790.
85. Cid MC, Schnaper HW, Kleinman HK. Estrogens and the vascular endothelium. Ann N Y Acad Sci 2002; 966: 143-157.
86. Losordo DW, Isner JM. Estrogen and angiogenesis: a review. Arterioscler Thromb Vasc Biol 2001; 21: 6-12.
87. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-182.
88. Peng L, Sun J, Wang WD, Jian ZX, Ou JR. Biological effect of ectopic expression of angiopoietin-1 and -2 in hepatocellular carcinoma cell line. Hepatobiliary Pancreat Dis Int 2003; 2: 94-97.
89. Stoeltzing O, Ahmad SA, Liu W, et al. Angiopoietin-1 inhibits tumour growth and ascites formation in a murine model of peritonea] carcinomatosis. Br J Cancer 2002; 87: 1182-1187.
90. Stoeltzing O, Ahmad SA, Liu W, et al. Angiopoietin-1 inhibits vascular permeability, angiogenesis and growth of hepatic colon cancer tumors. Cancer Res 2003; 63: 3370-3377.
91. Ahmed SA, Liu W, Jung YD, et al. The effects of angiopoietin-1 and -2 on tumour growth and angiogenesis in human colon cancer. Cancer Res 2001; 61: 1255-1259.
92. Hatanaka H, Abe Y, Kamiya T, et al. Clinical implications of interleukin (IL)-10 induced by non-small cell lung cancer. Ann Oncol 2000; 11: 815-819.
93. Yu Q, Stamenkovic I. Angiopoietin-2 is implicated in the regulation of tumor angiogenesis. Am J Pathol 2001; 158: 563-570.
94. Albrecht ED, Pepe GJ. Steroid hormone regulation of angiogenesis in the primate endometrium. Front Biosci 2003; 8: d416-429.
95. Siemeister G, Schirner M, Weindel K, et al. Two independent mechanisms essential for tumour angiogenesis: inhibition of human melanoma xenograft growth by interfering with either the vascular endothelial growth factor receptor or the Tie2 pathway. Cancer Res 1999; 59: 3185-3191.
96. Le Jan S, Amy C, Cazes A, et al. Angiopoietin-like 4 is a proangiogenic factor produced during ischemia and in conventional renal cell carcinoma. Am J Pathol 2003; 162: 1521-1528.